Usana Health Sciences Inc

Health Care
Medicinal Chemicals and Botanical Products
www.usanahealthsciences.com

Earnings Score
Moat Score

Market Cap $654.38M
PE 12
Debt -
Cash $367.74M
EV -
FCF $65.64M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$54.34M
EBIT	$92.53M
ROE	10%
ROA	14%
FCF	$65.64M
Equity	$533.09M
Growth Stability	61%
PE	12.04
PEG	-0.7
PB	1.23
P/FCF	9.97
P/S	0.76
Price/Cash	0.56
Net Margins	6%
Gross Margins	81%
Op. Margins	11%
Earnings CAGR	-5%
Sales Growth YoY	-6%
Sales Growth QoQ	-6%
Sales CAGR	-1%
FCF CAGR	-5%
Equity CAGR	6%
Earnings Stability	0.19
Earnings Growth YoY	-7%

Earnings Growth QoQ	2%
Earnings CAGR 5Y	-17%
Sales CAGR 5Y	-6%
FCF CAGR 5Y	-19%
Equity CAGR 5Y	9%
Earnings CAGR 3Y	-11%
Sales CAGR 3Y	-11%
FCF CAGR 3Y	-20%
Equity CAGR 3Y	13%
Market Cap	$654.38M
Revenue	$861.97M
Assets	$671.31M
Cash	$367.74M
Shares Outstanding	19.06M
Earnings Score	5%
Moat Score	89%
Working Capital	336.41M
Current Ratio	3.93
Gross Profit	$697.00M
Shares Growth 3y	-0%
Equity Growth QoQ	4%
Equity Growth YoY	13%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe, with the majority of its revenue generated from markets outside the United States.

SEC Filings

Direct access to Usana Health Sciences Inc (USNA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 28
- 10-Q Jun 29
- 10-Q Mar 30
2023
- 10-K Dec 30
- 10-Q Sep 30
- 10-Q Jul 01
- 10-Q Apr 01
2022
- 10-K Dec 31
- 10-Q Oct 01
- 10-Q Jul 02
- 10-Q Apr 02
- 10-K Jan 01

Sector Comparison

How does Usana Health Sciences Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Usana Health Sciences Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%

Stability 19%

loading chart...

Usana Health Sciences Inc Discounted Cash Flow

Fully customizable DCF calculator online for Usana Health Sciences Inc.

Years

Calculation mode

= $484M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$66M	$63M	$60M	$57M	$54M	$52M	$49M	$47M	$45M	$43M	$41M	$410M
DCF		$57M	$49M	$43M	$37M	$32M	$28M	$24M	$21M	$18M	$16M	$158M
Value	$484M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	12/2021	12/2022	12/2023	TTM
Net Margins	10%	10%	6%	11%	9%	11%	10%	7%	7%	6%
ROA	-	30%	26%	35%	29%	28%	30%	18%	16%	14%
ROE	-	31%	17%	32%	29%	28%	29%	16%	13%	10%

Bad Net Margins (5.86%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	100%	100%	100%	99%	61%	62%	61%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (61%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	10%	4%	14%	-11%	7%	5%	-16%	-8%	-6%
Earnings YoY growth	-	6%	-37%	102%	-20%	24%	-7%	-40%	-8%	-17%
Equity YoY growth	-	16%	12%	8%	-10%	26%	-11%	10%	14%	9%
FCF YoY growth	-	19%	6%	27%	-22%	32%	-25%	-14%	-40%	-19%